Untitled

Kouloulias, Vassilis; Nikita, Konstantina S.; Kouvaris, John; Uzunoglu, N.K.; Golematis, V.; Papavasiliou, C.; Vlahos, Lambros

doi:10.1007/s005340100026

Cited by 8 publications

(4 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The median OS of the mEHT group was 18 months (range = 1.5-68 months) and was in agreement with 18.5 months of Kouloulias et al 56 and 18.6 months of Ohguri et al 33 The OS analysis of 201 patients in the 14 published studies on hyperthermia for pancreatic cancer treatment showed an overall median survival 10.5 months (range = 1-53 months), 21 which was lower than the median OS (18 months) of mEHT group as reported in the present study. The survival curves after a certain period converge because the therapies both with and without mEHT have selected the patients with more favorable characteristics.…”

Section: Discussionsupporting

confidence: 90%

“…This low mEHT toxicity correlation has been shown also in previous studies. 21,32-35,54-56 This may suggest a better safety of the mEHT than the conventional hyperthermia that resulted in 935 complains from 70 hyperthermia treatments as reported in a recent study. 56…”

Section: Discussionmentioning

confidence: 65%

“…Hyperthermia enhances the effects of chemo-radiotherapies in pancreatic cancers, increasing overall and progression-free survival. 33-35,56,57 mEHT allows use of a lower power than conventional hyperthermia 41,58 and can be applied with good results for pancreatic cancer treatment. 47-50…”

Section: Discussionmentioning

confidence: 99%

“…21 The present study showed a 64.7% of PR in mEHT group that was close to the 57% and 60% reported by Kouloulias and colleagues in 2 different studies. 56,57…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Modulated Electro-Hyperthermia as Palliative Treatment for Pancreatic Cancer: A Retrospective Observational Study on 106 Patients

et al. 2019

View full text Add to dashboard Cite

Background: Pancreatic adenocarcinoma has a poor prognosis, resulting in a <10% survival rate at 5 years. Modulated electro-hyperthermia (mEHT) has been increasingly used for pancreatic cancer palliative care and therapy. Objective: To monitor the efficacy and safety of mEHT for the treatment of advanced pancreatic cancer. Methods: We collected data retrospectively on 106 patients affected by stage III-IV pancreatic adenocarcinoma. They were divided into 2 groups: patients who did not receive mEHT (no-mEHT) and patients who were treated with mEHT. We performed mEHT applying a power of 60 to 150 W for 40 to 90 minutes. The mEHT treatment was associated with chemotherapy and/or radiotherapy for 33 (84.6%) patients, whereas 6 (15.4%) patients received mEHT alone. The patients of the no-mEHT group received chemotherapy and/or radiotherapy in 55.2% of cases. Results: Median age of the sample was 65.3 years (range = 31-80 years). After 3 months of therapy, the mEHT group had partial response in 22/34 patients (64.7%), stable disease in 10/34 patients (29.4%), and progressive disease in 2/34 patients (8.3%). The no-mEHT group had partial response in 3/36 patients (8.3%), stable disease in 10/36 patients (27.8%), and progressive disease in 23/36 patients (34.3%). The median overall survival of the mEHT group was 18.0 months (range = 1.5-68.0 months) and 10.9 months (range = 0.4-55.4 months) for the non-mEHT group. Conclusions: mEHT may improve tumor response and survival of pancreatic cancer patients.

show abstract

Section: Discussionsupporting

confidence: 90%

Section: Discussionmentioning

confidence: 65%

Section: Discussionmentioning

confidence: 99%

“…21 The present study showed a 64.7% of PR in mEHT group that was close to the 57% and 60% reported by Kouloulias and colleagues in 2 different studies. 56,57…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations